| Literature DB >> 28099864 |
Tom L Stephen1, Kyle K Payne1, Ricardo A Chaurio1, Michael J Allegrezza1, Hengrui Zhu2, Jairo Perez-Sanz1, Alfredo Perales-Puchalt1, Jenny M Nguyen1, Ana E Vara-Ailor1, Evgeniy B Eruslanov3, Mark E Borowsky4, Rugang Zhang2, Terri M Laufer5, Jose R Conejo-Garcia6.
Abstract
Despite the importance of programmed cell death-1 (PD-1) in inhibiting T cell effector activity, the mechanisms regulating its expression remain poorly defined. We found that the chromatin organizer special AT-rich sequence-binding protein-1 (Satb1) restrains PD-1 expression induced upon T cell activation by recruiting a nucleosome remodeling deacetylase (NuRD) complex to Pdcd1 regulatory regions. Satb1 deficienct T cells exhibited a 40-fold increase in PD-1 expression. Tumor-derived transforming growth factor β (Tgf-β) decreased Satb1 expression through binding of Smad proteins to the Satb1 promoter. Smad proteins also competed with the Satb1-NuRD complex for binding to Pdcd1 enhancers, releasing Pdcd1 expression from Satb1-mediated repression, Satb1-deficient tumor-reactive T cells lost effector activity more rapidly than wild-type lymphocytes at tumor beds expressing PD-1 ligand (CD274), and these differences were abrogated by sustained CD274 blockade. Our findings suggest that Satb1 functions to prevent premature T cell exhaustion by regulating Pdcd1 expression upon T cell activation. Dysregulation of this pathway in tumor-infiltrating T cells results in diminished anti-tumor immunity.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28099864 PMCID: PMC5336605 DOI: 10.1016/j.immuni.2016.12.015
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745